SHP2 inhibition and adjuvant therapy synergistically target KIT‐mutant GISTs via ERK1/2‐regulated GSK3β/cyclin D1 pathway.
Saved in:
| Title: | SHP2 inhibition and adjuvant therapy synergistically target KIT‐mutant GISTs via ERK1/2‐regulated GSK3β/cyclin D1 pathway. |
|---|---|
| Authors: | He, Chunxiao1 (AUTHOR), Yu, Jiaying1 (AUTHOR), Mao, Shuang1 (AUTHOR), Yang, Shaohua2 (AUTHOR), Jiang, Xianming2 (AUTHOR), Huang, Lei3 (AUTHOR), Li, Mingzhe2 (AUTHOR), He, Yulong2 (AUTHOR) heyulong@mail.sysu.edu.cn, Zhang, Xinhua4 (AUTHOR) zhangxinhua@mail.sysu.edu.cn, Xiang, Xi1 (AUTHOR) xiangx25@mail.sysu.edu.cn |
| Source: | Clinical & Translational Medicine. Feb2025, Vol. 15 Issue 2, p1-19. 19p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
